12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The First Saudi Study Investigating the Plasmid-borne Aminoglycoside and Sulfonamide Resistance among Acinetobacter baumannii Clinical Isolates Genotyped by RAPD-PCR: the Declaration of a Novel Allelic Variant Called aac(6ʹ)-SL and Three Novel Mutations in the sul1 Gene in the Acinetobacter Plasmid (s)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Acinetobacter baumannii ( A. baumannii) is one of the most important nosocomial pathogens responsible for a wide range of infections.

          Aim

          This study aimed to investigate the existence of the plasmidic genes encoding for aminoglycoside modifying enzymes (AMEs), 16S rRNA methyltransferases (RMT), and the altered dihydropetroate synthase (DHPS) encoded by the sul1 gene among A. baumannii clinical isolates collected from Taif, Kingdom of Saudi Arabia (KSA). The mutations in  aac(6ʹ)-Ib and sul1 genes were also investigated.

          Methods

          Forty A. baumannii clinical isolates were investigated for their susceptibility to ten antibiotics. The plasmid DNA was extracted and screened for nine genes encoding for aminoglycoside resistance in addition to the sul1 gene. The clonal relatedness was determined by random amplified polymorphic DNA (RAPD)-PCR. Mutation in aac(6ʹ)-Ib and the sul1 genes were detected by capillary electrophoresis sequencing (CES).

          Results

          All isolates were A. baumannii in which 42.5% of them exhibited a high level of aminoglycoside resistance (HLAR). The most prevalent AMEs and RMT encoding genes were aph(3ʹ)-VI, the two aac(6ʹ) gene variants [ aac(6ʹ)-Ib and aac(6ʹ)-SL], ant(3ʹʹ)-I, and armA in which 90%, 87.5%, 85%, and 45% of isolates tested positive, respectively. The other investigated aminoglycoside resistant encoding genes, namely aac(3)-II, aac(6ʹ)-II, and rmtB, were not detected. Only 15% of isolates harbored the sul1 gene. RAPD-PCR classified the 40 isolates into three clusters in which cluster II was the main cluster. DNA sequencing revealed that 34.29% (12/35) of isolates tested positive for aac(6ʹ)-Ib were found to harbor a common missense mutation in position 102 indicating a novel allelic variant named aac(6ʹ)-SL. Also, DNA sequencing revealed three missense mutations in the sul1 gene.

          Conclusion

          This is the first Saudi study to investigate the plasmid borne aminoglycoside and sulfonamide resistance genes among A. baumannii clinical isolates. A novel allelic variant for aac(6ʹ)-Ib was detected in addition to novel mutations in the sul1 gene.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Jalview Version 2—a multiple sequence alignment editor and analysis workbench

          Summary: Jalview Version 2 is a system for interactive WYSIWYG editing, analysis and annotation of multiple sequence alignments. Core features include keyboard and mouse-based editing, multiple views and alignment overviews, and linked structure display with Jmol. Jalview 2 is available in two forms: a lightweight Java applet for use in web applications, and a powerful desktop application that employs web services for sequence alignment, secondary structure prediction and the retrieval of alignments, sequences, annotation and structures from public databases and any DAS 1.53 compliant sequence or annotation server. Availability: The Jalview 2 Desktop application and JalviewLite applet are made freely available under the GPL, and can be downloaded from www.jalview.org Contact: g.j.barton@dundee.ac.uk
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

            SUMMARYAcinetobacter is a complex genus, and historically, there has been confusion about the existence of multiple species. The species commonly cause nosocomial infections, predominantly aspiration pneumonia and catheter-associated bacteremia, but can also cause soft tissue and urinary tract infections. Community-acquired infections by Acinetobacter spp. are increasingly reported. Transmission of Acinetobacter and subsequent disease is facilitated by the organism's environmental tenacity, resistance to desiccation, and evasion of host immunity. The virulence properties demonstrated by Acinetobacter spp. primarily stem from evasion of rapid clearance by the innate immune system, effectively enabling high bacterial density that triggers lipopolysaccharide (LPS)-Toll-like receptor 4 (TLR4)-mediated sepsis. Capsular polysaccharide is a critical virulence factor that enables immune evasion, while LPS triggers septic shock. However, the primary driver of clinical outcome is antibiotic resistance. Administration of initially effective therapy is key to improving survival, reducing 30-day mortality threefold. Regrettably, due to the high frequency of this organism having an extreme drug resistance (XDR) phenotype, early initiation of effective therapy is a major clinical challenge. Given its high rate of antibiotic resistance and abysmal outcomes (up to 70% mortality rate from infections caused by XDR strains in some case series), new preventative and therapeutic options for Acinetobacter spp. are desperately needed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Aminoglycosides: An Overview.

              Aminoglycosides are natural or semisynthetic antibiotics derived from actinomycetes. They were among the first antibiotics to be introduced for routine clinical use and several examples have been approved for use in humans. They found widespread use as first-line agents in the early days of antimicrobial chemotherapy, but were eventually replaced in the 1980s with cephalosporins, carbapenems, and fluoroquinolones. Aminoglycosides synergize with a variety of other antibacterial classes, which, in combination with the continued increase in the rise of multidrug-resistant bacteria and the potential to improve the safety and efficacy of the class through optimized dosing regimens, has led to a renewed interest in these broad-spectrum and rapidly bactericidal antibacterials.
                Bookmark

                Author and article information

                Journal
                Infect Drug Resist
                Infect Drug Resist
                idr
                Infection and Drug Resistance
                Dove
                1178-6973
                12 November 2021
                2021
                : 14
                : 4739-4756
                Affiliations
                [1 ]Department of Microbiology and Immunology, Faculty of Pharmacy, University of Sadat City , Sadat City, Menoufia, 32897, Egypt
                [2 ]Department of Microbiology and Immunology, Faculty of Pharmacy, Misr University for Science and Technology , 6th of October City, Egypt
                [3 ]Department of Chemistry, Faculty of Science, Benha University , Benha, 13508, Egypt
                [4 ]Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Sadat City , Sadat City, Menoufia, 32897, Egypt
                [5 ]Department of Clinical Pharmacy, College of Pharmacy, Taif University , Taif, 21974, Saudi Arabia
                Author notes
                Correspondence: Mohamed F El-Badawy Department of Microbiology and Immunology, Faculty of Pharmacy, University of Sadat City , Sadat City, Menoufia, 32897 Egypt Tel +20 103-205-9964 Email Mohamed.Elbadawy@fop.usc.edu.eg
                Author information
                http://orcid.org/0000-0002-5896-3067
                http://orcid.org/0000-0003-1189-1542
                Article
                324707
                10.2147/IDR.S324707
                8594745
                34795490
                e451a984-08e7-4cf5-8ffa-fac358ed5657
                © 2021 El-Badawy et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 07 July 2021
                : 09 September 2021
                Page count
                Figures: 6, Tables: 8, References: 61, Pages: 18
                Categories
                Original Research

                Infectious disease & Microbiology
                ames,arma,rapd-pcr,a. baumannii,16s rrna
                Infectious disease & Microbiology
                ames, arma, rapd-pcr, a. baumannii, 16s rrna

                Comments

                Comment on this article